Overview

Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma

Status:
Withdrawn

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

This study is a Phase I trial of Darinaparsin in combination with CHOP for the treatment of lymphoma. Eligible patients will not have had any previous anti-cancer treatment and will be eligible to receive CHOP alone.

Phase:

Phase 1

Details

Lead Sponsor:

Ziopharm

Treatments:

Cyclophosphamide
Doxorubicin
Prednisone
Vincristine